Human umbilical cord mesenchymal stem cells secretome and nanoemulsion propolis combination ameliorate osteoclastogenesis in lipopolysaccharide-induced osteolysis in hyperglycemia rats.

BACKGROUND/PURPOSE: Human umbilical cord mesenchymal stem cell secretome (HUCMSCS) and nanoemulsion propolis (NEP) from Tetragonula biroi may be beneficial regenerative medicine to reduce LPS-induced osteolysis with hyperglycemia. This study aimed to investigate the HUCMSCS and NEP effect on nuclear factor associated T-cell-1 (NFATc1), sclerostin, receptor activator kappa beta (RANK), its ligand (RANKL), the osteoprotegerin (OPG) expression, tartrate-resistant acid phosphatase (TRAPase), and cathepsin K (Ctsk) serum level in LPS-induced osteolysis in hyperglycemic Wistar rats (Rattus novergicus).

MATERIALS AND

METHODS

Twenty-eight healthy male Wistar rats, 1-2 months old and 250-300 g body weight, were divided into seven groups, namely K1: control group; K2: 100 μl LPS; K3: hyperglycemia (≥230 mg/dL); K4: 100 μl LPS with hyperglycemia; K5: LPS, hyperglycemia, and 100 μl NEP; K6: LPS, hyperglycemia, and 100 μl HUCMSCS; and K7: LPS, hyperglycemia, and 100 μl HUCMSCS and NEP. Escherichia coli`s LPS was used to induce osteolysis on the calvaria. NEP and HUCMSCS were formulated and collected, then injected subcutaneously on the calvaria. Hyperglycemia-induced streptozotocin 30 mg/kg injection for one week, intraperitoneally. All samples were sacrificed on day 8. Blood samples were collected to examine TRAP and Ctsk levels with enzyme-linked immunosorbent assay. NFATc1, sclerostin, and RANK-RANKL-OPG expression investigated with immunohistochemistry.

RESULTS

HUCMSCS and NEP administration inhibit TRAP and Ctsk levels, reduce NFATc1, sclerostin, and RANK-RANKL, but enhance OPG expression in LPS-induced osteolysis with hyperglycemia with significant differences between groups (P ≤ 0.05).

CONCLUSION

HUCMSCS and NEP post-administration reduced osteoclastogenesis in LPS-induced osteolysis calvaria with hyperglycemic in rats in the early phase of bone remodelling.